Related Experiment Video
Updated: Jun 18, 2025

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
Alfredo Caturano1, Erica Vetrano1, Raffaele Galiero1
1Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", I-80138 Naples, Italy.
Insights
Cardiac hypertrophy, a response to increased heart workload, can lead to heart failure. Understanding its molecular mechanisms is key for developing new therapies to prevent and reverse this condition.
Area of Science:
- Cardiology
- Molecular Biology
- Pathophysiology
Background:
- Cardiac hypertrophy is an adaptive response to increased workload, aiming to reduce ventricular wall stress.
- Persistent stimuli can cause pathological hypertrophy, leading to heart failure, impaired function, and increased mortality.
- Diabetic cardiomyopathy involves pathological hypertrophy driven by insulin resistance, hyperglycemia, and associated metabolic and inflammatory changes.
Purpose of the Study:
- To review the molecular mechanisms underlying pathological cardiac hypertrophy.
- To explore how these mechanisms contribute to conditions like diabetic cardiomyopathy.
- To identify potential therapeutic targets for preventing and reversing cardiac hypertrophy.
Main Methods:
- Literature review of molecular mechanisms in pathological cardiac hypertrophy.
- Analysis of pathophysiological pathways including cell death, fibrosis, and metabolic alterations.
- Examination of the role of insulin resistance and hyperglycemia in diabetic cardiomyopathy.
Main Results:
- Pathological hypertrophy involves complex mechanisms: cell death, fibrosis, mitochondrial dysfunction, altered metabolism, and impaired quality control.
- Fetal gene reactivation, sarcomere disorganization, and inadequate angiogenesis are key features.
- Diabetic cardiomyopathy highlights the impact of metabolic dysregulation on cardiac remodeling.
Conclusions:
- Understanding the molecular basis of pathological hypertrophy is crucial for therapeutic development.
- Targeting specific pathways could offer novel strategies for treating and preventing heart failure.
- Interventions may focus on metabolic correction, improving protein/mitochondrial quality, and modulating inflammatory responses.
Abstract:
Cardiac hypertrophy develops in response to increased workload to reduce ventricular wall stress and maintain function and efficiency. Pathological hypertrophy can be adaptive at the beginning. However, if the stimulus persists, it may progress to ventricular chamber dilatation, contractile dysfunction, and heart failure, resulting in poorer outcome and increased social burden. The main pathophysiological mechanisms of pathological hypertrophy are cell death, fibrosis, mitochondrial dysfunction, dysregulation of -handling proteins, metabolic changes, fetal gene expression reactivation, impaired protein and mitochondrial quality control, altered sarcomere structure, and inadequate angiogenesis. Diabetic cardiomyopathy is a condition in which cardiac pathological hypertrophy mainly develop due to insulin resistance and subsequent hyperglycaemia, associated with altered fatty acid metabolism, altered calcium homeostasis and inflammation. In this review, we summarize the underlying molecular mechanisms of pathological hypertrophy development and progression, which can be applied in the development of future novel therapeutic strategies in both reversal and prevention.
Related Concept Videos
Pathophysiology of Heart Failure
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Pathophysiology of Cardiac Performance
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers

